Loading
Lymphatic System and Diseases / Lymphatic Disorders and Treatments / Diagnosis and Treatment of Venous Diseases · Review
Journal of Obstetrics and Gynaecology · September 7, 2026
Encouraging direction, but not yet definitive.
This meta-analysis of 15 RCTs demonstrates that Meridian Sinew Tuina (MST), a deep-tissue manual therapy, significantly reduces upper limb circumference and improves swelling response rates in breast cancer-related lymphedema compared to controls, with moderate certainty for primary outcomes and no serious adverse events reported. However, the evidence is substantially weakened by performance bias (lack of blinding) and heterogeneous control interventions, and the authors conclude MST is suitable only as a supportive adjunctive therapy within oncological rehabilitation, not as standalone treatment.
Systematic review and meta-analysis of randomized controlled trials. Randomised controlled trials evaluating MST (deep tissue mobilisation along six-hand meridian sinew lines via plucking, kneading, and pressing) versus controls in patients with breast cancer-related lymphedema.. Intervention: Meridian Sinew Tuina (MST): deep tissue mobilisation along the six-hand meridian sinew (Jingjin) lines via plucking, kneading, and pressing techniques.. Compared with: Control interventions (unspecified across included trials; varied control group protocols noted as source of heterogeneity).. Global (searches included Chinese, English, and other international databases; no restriction on trial location specified)..
MST reduced upper limb circumference versus controls with SMD = 1.59 (95% CI: 1.44–1.74, p < 0.0001, I² = 0.0%, N = 924; moderate certainty) Clinical Response Efficacy Rate (≥30% swelling reduction and symptom relief) favoured MST with RR = 1.69 (95% CI: 1.54–1.87, p < 0.0001, I² = 0.0%, N = 1,114; moderate certainty) Secondary outcomes at 3 months showed MST improvements in DASH functional scores (SMD = −1.81, 95% CI: −2.11 to −1.51, I² = 45.1%), pain intensity (SMD = −2.44, 95% CI: −2.93 to −1.95, I² = 50.4%), and quality of life (SMD = 1.04, 95% CI: 0.79–1.29, I² = 0.0%)
Source does not report adverse event rates, dropout rates, or details of MST protocol standardization across the 15 trials. No serious adverse events were reported across included trials
Clinicians may consider MST as an adjunctive supportive tool within existing lymphedema rehabilitation protocols, particularly where swelling and functional restriction persist despite standard CDT. The evidence does not support MST as a replacement for standard care, and adoption should await trials with active blinding and standardized control arms.
Meta-analysis of 15 RCTs shows consistent, moderate-certainty evidence for MST reducing limb circumference and swelling, but unblinded performance bias and heterogeneous controls limit confidence; suitable for adjunctive use pending higher-quality trials.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians may consider MST as an adjunctive supportive tool within existing lymphedema rehabilitation protocols, particularly where swelling and functional restriction persist despite standard CDT. The evidence does not support MST as a replacement for standard care, and adoption should await trials with active blinding and standardized control arms.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Complex Decongestive Therapy (CDT) is the non-operative standard for breast cancer-related lymphedema (BCRL), but many patients experience persistent subcutaneous stiffness, pain, and restricted mobility. This study systematically reviews the safety and clinical efficacy of Meridian Sinew Tuina (MST) protocols for BCRL.Methods Global and regional databases (PubMed, Cochrane Library, Embase, Web of Science, CNKI, Wanfang, VIP) were searched from inception to January 15, 2026, with alerts monitored through April 30, 2026. Randomised controlled trials (RCTs) evaluating MST (deep tissue mobilisation along the six-hand meridian sinew [Jingjin] lines via plucking, kneading, and pressing) were included. Two reviewers independently extracted data, evaluated risk of bias using Cochrane RoB 2, and assessed evidence certainty via GRADE using a random-effects model.Results Fifteen RCTs were included. For the primary anthropometric outcome, MST significantly reduced upper limb circumference compared to controls (SMD = 1.59; 95% CI: 1.44 to 1.74; Z = 20.81; p < 0.0001; I2=0.0%; N = 924; GRADE: Moderate certainty). The Clinical Response Efficacy Rate (≥ 30% swelling reduction and symptom relief) favoured MST (RR = 1.69; 95% CI: 1.54 to 1.87; Z = 10.62; p < 0.0001; I2=0.0%; N = 1,114; GRADE: Moderate certainty). Trial Sequential Analysis confirmed sample size sufficiency. For secondary outcomes (N = 924; GRADE: Low to Very Low certainty due to performance bias and clinical heterogeneity), MST showed favourable 3-month improvements in DASH functional scores (SMD = −1.81; 95% CI: −2.11 to −1.51; I2=45.1%), pain intensity (SMD = −2.44; 95% CI: −2.93 to −1.95; I2=50.4%), and quality of life (SMD = 1.04; 95% CI: 0.79 to 1.29; I2=0.0%). No serious adverse events occurred.Conclusions MST protocols are associated with favourable short- and mid-term reductions in upper limb swelling. However, confidence is tempered by unblinded performance bias and control group variations. MST cannot be unconditionally recommended for standalone implementation but represents a promising, optional supportive adjunctive intervention within oncological rehabilitation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.